DiscoveryProbe™ FDA-approved Drug Library: Structured Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds with confirmed regulatory approval or pharmacopeial listing [Product Page]. Each compound is provided as a 10 mM DMSO solution, with stability demonstrated for 12 months at -20°C and up to 24 months at -80°C. The library covers diverse mechanisms of action, including receptor modulation, enzyme inhibition, and signal pathway regulation. It is optimized for high-throughput and high-content screening, supporting drug repositioning and target discovery (Zhang et al., 2023). All compounds are sourced from regulatory-approved lists (FDA, EMA, HMA, CFDA, PMDA), ensuring translational relevance and reliability.

Biological Rationale

Drug discovery increasingly leverages repurposing of existing compounds to accelerate translational breakthroughs. FDA-approved bioactive compound libraries, such as the DiscoveryProbe™ FDA-approved Drug Library, provide a foundation for identifying new indications for established drugs [Related Article]. These libraries consolidate regulatory-vetted molecules with known safety and pharmacokinetic profiles, streamlining early-phase screening and reducing attrition rates in clinical development. Their diversity of mechanisms—ranging from receptor agonists/antagonists to enzyme inhibitors—mirrors the complexity of biological systems targeted in oncology, neurodegenerative disease, and beyond. The library's format (pre-dissolved, arrayed solutions) further enables direct integration with automated screening platforms, supporting both high-throughput (HTS) and high-content screening (HCS) modalities. This article extends the analysis found in 'DiscoveryProbe FDA-approved Drug Library: Unveiling New Targets' by providing structured, atomic evidence and explicit workflow parameters for translational teams.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds that modulate a spectrum of biological targets. Mechanisms represented include:

• Receptor agonists/antagonists: Compounds that bind to and modulate the activity of G protein-coupled receptors, nuclear hormone receptors, and ion channels.
• Enzyme inhibitors: Small molecules that inhibit kinases, proteases (e.g., viral 3C/3CL proteases), and other catalytic proteins. For example, telaprevir and trifluridine inhibit viral 3C proteases, disrupting viral replication (Zhang et al., 2023).
• Signal pathway regulators: Drugs that modulate key signaling cascades, including MAPK, PI3K/AKT, and mTOR pathways.
• Ion channel modulators: Molecules that alter the flux of ions across cell membranes, impacting excitability and cellular signaling.

Notable examples include doxorubicin (topoisomerase II inhibitor), metformin (AMPK pathway activator), and atorvastatin (HMG-CoA reductase inhibitor). The diversity of mechanisms supports broad application across disease models and target identification workflows [See also: Target Identification].

Evidence & Benchmarks

• DiscoveryProbe™ FDA-approved Drug Library enables high-throughput screening (HTS) of 2,320 clinically-approved compounds in 96-well and deep-well plate formats [Product Page].
• Telaprevir and trifluridine were identified as novel inhibitors of poliovirus 3C protease using a dual FRET and stress granule (SG) system (Zhang et al., 2023, Table 1).
• Compounds are supplied in 10 mM DMSO, stable for 12 months at -20°C and 24 months at -80°C; shipping is on blue ice (evaluation samples) or at room temperature/on ice (other sizes) [Product Page].
• The library's compounds are curated from FDA, EMA, HMA, CFDA, and PMDA approvals or pharmacopeias, ensuring clinical relevance [Internal].
• Drug repositioning screens using FDA-approved libraries have identified compounds for oncology, neurodegeneration, and infectious diseases, exemplified by the discovery of Tideglusib as a novel helicase inhibitor in mechanistic screens [Thought Leadership].

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for:

• High-throughput screening (HTS) for drug repositioning and target identification in disease models (e.g., cancer, neurodegeneration, viral infection).
• Signal pathway modulation studies using well-characterized pharmacological agents.
• Validation and benchmarking of high-content screening (HCS) platforms with regulatory-vetted compounds.

Its use has accelerated the identification of inhibitors for viral proteases lacking human homologs, such as 3C/3CLpro (Zhang et al., 2023). For further discussion of translational acceleration, see 'Translational Acceleration Through Mechanistic Drug Libraries', which this article updates with new evidence from viral inhibitor screens.

Common Pitfalls or Misconceptions

• The library is not suitable for primary screening of novel chemical entities; it is restricted to clinically approved or listed compounds.
• Compounds are provided in DMSO; precipitation may occur if transferred to aqueous buffers without proper dilution.
• The library does not include proprietary or investigational drugs not yet approved in recognized regions.
• Not all compounds are active in every biological context; mechanism-of-action annotation does not guarantee efficacy in new disease models.
• HTS results require secondary validation, as off-target or cytotoxic effects may confound primary screens.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied in ready-to-use 10 mM DMSO solutions, arrayed in 96-well microplates, deep-well plates, or 2D barcoded tubes. Recommended storage is at -20°C for up to 12 months or -80°C for up to 24 months. Shipping for evaluation samples is on blue ice; other sizes are shipped at room temperature or on blue ice upon request. For high-throughput screening, compounds can be directly dispensed into assay plates using automated pipetting platforms. Standard screening concentrations range from 1–10 μM, depending on assay sensitivity and desired throughput. Validation in both biochemical and cell-based assays is supported by the library's annotation and format. Integration with FRET- or reporter-based readouts (e.g., viral protease assays) is documented in recent literature (Zhang et al., 2023).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers a uniquely curated, regulatory-validated resource for rapid drug screening, repositioning, and pharmacological target discovery. Its integration with HTS and HCS platforms, combined with robust annotation and proven stability, supports accelerated translational workflows in oncology, neurobiology, and infectious disease research. Future developments may include expansion to investigational agents and integration with AI-driven compound prioritization, but current scope is confined to approved or pharmacopeial-listed drugs. For further details and purchasing, visit the DiscoveryProbe™ FDA-approved Drug Library product page.